Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Payables (2020 - 2025)

Gain Therapeutics has reported Payables over the past 6 years, most recently at $1.6 million for Q3 2025.

  • Quarterly results put Payables at $1.6 million for Q3 2025, up 45.66% from a year ago — trailing twelve months through Sep 2025 was $1.6 million (up 45.66% YoY), and the annual figure for FY2024 was $900000.0, down 30.77%.
  • Payables for Q3 2025 was $1.6 million at Gain Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Payables for GANX hit a ceiling of $2.7 million in Q2 2025 and a floor of $560479.0 in Q4 2021.
  • Median Payables over the past 5 years was $1.3 million (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Payables: tumbled 41.71% in 2021 and later skyrocketed 185.47% in 2022.
  • Gain Therapeutics' Payables stood at $560479.0 in 2021, then skyrocketed by 185.47% to $1.6 million in 2022, then decreased by 18.75% to $1.3 million in 2023, then crashed by 30.77% to $900000.0 in 2024, then soared by 77.78% to $1.6 million in 2025.
  • The last three reported values for Payables were $1.6 million (Q3 2025), $2.7 million (Q2 2025), and $2.2 million (Q1 2025) per Business Quant data.